Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma.

BACKGROUND

Oncogenic mutations in the BRAF gene, particularly the V600E mutation, are present in roughly half of metastatic cutaneous melanoma cases. BRAF inhibitors (BRAFi) have shown significant clinical efficacy; however, their long-term effectiveness is frequently limited by the development of resistance. Parthenolide, a sesquiterpene lactone derived from medicinal herbs, has previously been reported to exhibit anti-melanoma effects and to disrupt signaling pathways associated with BRAFi resistance.

PURPOSE: This study aimed to evaluate the potential of parthenolide to overcome resistance to BRAFi in melanoma.

STUDY DESIGN AND

METHODS

The effects of parthenolide on BRAFi-resistant melanoma cells were assessed using cell viability, apoptosis, and cell cycle assays. In vivo efficacy and safety were evaluated in a BRAFi-resistant melanoma xenograft mouse model. Target identification and validation were performed using network pharmacology, molecular docking, surface plasmon resonance, and Western blotting.

RESULTS

Parthenolide inhibited cell viability and induced apoptosis and S-phase cell cycle arrest in BRAFi-resistant melanoma cells. In vivo, parthenolide significantly suppressed tumor growth and reduced tumor weight in BRAFi-resistant melanoma xenografts without apparent toxicity. Mechanistically, parthenolide stably interacted with the N-terminal ATPase domain of Hsp90α and dose-dependently inhibited its ATPase activity. Hsp90α functions as a chaperone for several oncoproteins involved in signaling pathways driving BRAFi resistance. Parthenolide reduced the levels of several Hsp90α client proteins and inhibited their downstream pathways, including PI3K/Akt, Ras/Raf/MEK, and Src/STAT3, in BRAFi-resistant melanoma cells. Moreover, the Hsp90 activator tamoxifen attenuated the effects of parthenolide in these cells.

CONCLUSION

Our findings provide the first evidence that parthenolide can overcome BRAFi resistance in melanoma, highlighting its potential as a lead compound for the development of Hsp90α inhibitors to manage BRAFi-resistant cutaneous melanoma.